SCHEDULE: Vanguard Discloses 8.47% Stake in Organon & Co

Vanguard Portfolio Management has reported beneficial ownership of 22,052,559 shares, representing 8.47% of Organon & Co's common stock, as of March 31, 2026.

Summary

• Vanguard Portfolio Management, along with its affiliates Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC, has disclosed a significant beneficial ownership stake in Organon & Co.
• The filing indicates beneficial ownership of 22,052,559 shares of Organon & Co's common stock.
• This holding represents 8.47% of the total class of securities.
• Vanguard Portfolio Management has sole dispositive power over all 22,052,559 shares.
• The reporting entity has sole voting power over 206,523 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports existing beneficial ownership rather than new strategic developments or financial performance.

Positives

• Vanguard's substantial investment suggests confidence in Organon & Co's long-term prospects.
• The disclosure of sole dispositive power indicates significant control over the investment decisions for these shares.

Risks

• Potential for future changes in Vanguard's holdings, which could impact Organon & Co's stock price.
• As a large institutional holder, Vanguard's investment strategy shifts could influence market perception and trading activity.

Future Outlook

This filing is a snapshot of beneficial ownership as of a specific date and does not contain forward-looking statements or guidance from Organon & Co. It reflects Vanguard's current investment position.

Industry Context

StockSavvy.ai notes that large institutional holdings, such as this one by Vanguard, are common in the pharmaceutical and healthcare sectors, indicating significant investor interest in established companies like Organon & Co.

Comparison to Industry Standards

• Vanguard's 8.47% stake is a substantial holding for an institutional investor in the pharmaceutical sector. Many large-cap pharmaceutical companies typically see their largest institutional holders own between 5% and 15% of outstanding shares.
• For comparison, other major pharmaceutical companies often have BlackRock, State Street, and Vanguard as top holders, with stakes frequently falling within a similar range to this filing.

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's stake, which can influence market perception and stock liquidity. Any future changes in Vanguard's holdings could impact share price.
• Management: The presence of a large, stable holder like Vanguard can provide a degree of stability and may influence corporate governance discussions.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Vanguard will continue to hold or adjust its position in Organon & Co's common stock based on its investment strategies.
• Organon & Co will continue its operations and financial reporting as a publicly traded entity.

Key Dates

Keywords

Organon & Co, Vanguard Portfolio Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management